Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial

(2019) Luis Puig et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

(2018) Laura Sawyer et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2018) Ireny Y.K. Iskandar et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry

(2018) Bruce Strober et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

CME Part II Psoriasis: Which Therapy for Which Patient Focus on special populations and chronic infections

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The Evolving Landscape of Psoriasis Treatment

(2018) April W. Armstrong et al.   SEMINARS IN CUTANEOUS MEDICINE AND SURGERY

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR

(2018) Kayleigh J. Mason et al.   JAMA Dermatology

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab

(2017) Boni E. Elewski et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients

(2017) Michael Abrouk et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study

(2016) Hidemi Nakagawa et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis

(2016) L. Puig et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

(2016) A. Menter et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2015) Richard B. Warren et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Psoriasis prevalence among adults in the United States

(2014) Tara D. Rachakonda et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory

(2013) K.B. Gordon et al.   BRITISH JOURNAL OF DERMATOLOGY

Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies

(2013) P.L. Mattei et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011

(2012) April W. Armstrong et al.   PLoS One